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Abstract To investigate the impact of continuous glucose
monitoring (CGM) on health-related quality of life
(HRQOL), treatment satisfaction (TS) medical resource
use, and indirect costs in the SWITCH study. SWITCH was
a multicentre, randomized, crossover study. Patients with
type 1 diabetes (n = 153) using continuous subcutaneous
insulin infusion (CSII) were randomized to a 12 month
sensor-On/Off or sensor-Off/On sequence (6 months each
treatment), with a 4-month washout between periods.
HRQOL in children and TS in adults were measured using
validated questionnaires. Medical resource utilization data
were collected. In adults, TS was significantly higher in the
sensor-On arm, and there were significant improvements in
ratings for treatment convenience and flexibility. There
were no clinically significant differences in children’s
HRQOL or parents’ proxy ratings. The incidence of severe
hypoglycaemia, unscheduled visits, or diabetes-related
hospitalizations did not differ significantly between the two
arms. Adult patients made fewer telephone consultations
during the sensor-On arm; children’s caregivers made
similar numbers of telephone consultations during both
arms, and calls were on average only 3 min longer during
the sensor-On arm. Regarding indirect costs, children with
[70 % sensor usage missed fewer school days, compared
with the sensor-Off arm (P = 0.0046) but there was no
significant difference in the adults days of work off. The
addition of CGM to CSII resulted in better metabolic
control without imposing an additional burden on the
patient or increased medical resource use, and offered the
potential for cost offsets.
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Introduction
The diabetes control and complications trial (DCCT) has
clearly shown that intensive glycaemic control reduces the
risk of microvascular and macrovascular complications in
patients with type 1 diabetes mellitus [1, 2], but such
control is often difficult to achieve [2–4]. In recent years,
intensive glycaemic control has been facilitated by tech-
nological developments such as continuous subcutaneous
insulin infusion (CSII) [5] and continuous glucose moni-
toring (CGM) [6].
When attempting to establish optimal glycaemic con-
trol, different challenges arise depending on the age of
the patient. Glycaemic control may be particularly dif-
ficult to achieve in children, because of the unpredict-
ability of blood glucose levels, even with pump therapy,
and patient or caregiver concerns about hypoglycaemia
[7]. CSII is a safe and effective therapy providing
physiological insulin delivery and features that assist
improved diabetes management [8, 9]. In children, the
risk of serious adverse events is similar between MDI
and CSII [10]. The rate of discontinuation of pump
therapy in children and adolescents has been associated
with failure to improve HbA1c [8]. The recent SWITCH
(Sensing with Insulin pump Therapy to Control HbA1c)
study investigated the impact on metabolic control of
combining CGM with CSII therapy in a mixed popula-
tion of paediatric and adult patients with type 1 diabetes
[11]. This study showed that the combination of CGM
with CSII resulted in significant reductions in mean
HbA1c levels and in the proportion of time with hypo-
glycaemia in both children and adults, compared
with CSII alone. After 6 months, the mean decrease in
HbA1c during CGM was -0.4 %, 95 % CI -0.3,
-0.6 %, (-5 mmol/mol, 95 % CI -4, -6 mmol/mol)
(P \ 0.001). The mean decreases in adults and children
were -0.4 %, 95 % CI -0.3, -0.5 % (-4 mmol/mol,
95 % CI -3, -6 mmol/mol) and -0.5 %, 95 % CI
-0.3, -0.7 % (-5 mmol/mol, 95 % CI -3, -7 mmol/
mol), respectively. In addition, the total number of
boluses per day was significantly larger (6.8 ± 2.5 vs
5.8 ± 1.9, P \ 0.0001) during the sensor-On arm, com-
pared with the sensor-Off arm, but the mean total daily
insulin dose did not differ significantly between the two
arms, indicating a change in therapy management by the
subjects. There was no significant difference in the
incidence of severe hypoglycaemic events or diabetic
ketoacidosis events between the two arms [11].
In the current environment, improving outcomes and
demonstrating value are crucial for the introduction of new
technologies such as CGM into clinical practice. For this
reason, we assessed the effects of CGM on health-related
quality of life (HRQOL), treatment satisfaction, medical
resource utilization, and time lost from school or work. The
cross-over population of the SWITCH study gave a unique
opportunity to perform this analysis using validated age-
specific questionnaires.
Methods
Details of the SWITCH study have been presented in full
elsewhere [12]. In brief, the study was a randomized,
controlled, crossover study involving patients aged
between 6 and 70 years with type 1 diabetes of more than
1 year and an HbA1c level between 7.5 and 9.5 %
(59–80 mmol/mol). All patients had been using CSII with
rapid-acting insulin analogues for at least 6 months, but
had not previously used CGM. In addition, all patients had
successfully completed a five-question multiple-choice test
concerning pump therapy and general understanding of
diabetes. Following a 1-month run-in period, patients were
randomized to CGM sensor-On/sensor-Off or sensor-Off/
sensor-On treatment sequences for 6 months each, with a
4-month washout phase between the two periods to mini-
mize potential carryover effects. All patients used an
insulin pump system (Mini-Med Paradigm REAL-Time
System and Medtronic SofSensor; Medtronic, Tolochenaz,
Switzerland) throughout the study. Data were uploaded
using diabetes management software (CareLink Therapy
Management System for Diabetes—Clinical; Medtronic,
Tolochenaz, Switzerland) at scheduled study visits which
took place at 6-week intervals during each treatment per-
iod. Patients used a continuous glucose monitor (Guardian
REAL-Time Clinical; Medtronic, Tolochenaz, Switzer-
land), to which they were blinded (the device screen was
switched off) for 2 weeks prior to randomization, prior to
the second study period (i.e. during the crossover period),
and during the sensor-Off arm. No fixed treatment algo-
rithms were provided to the participants. The centre vari-
able was significant in the ANOVA model (P \ 0.0001);
however, the interaction of centre and treatment was not
(P = 0.9306) [11].
Measurement of HRQOL and treatment satisfaction
HRQOL in children and adolescents (age B18 years) was
measured by means of the Paediatric Quality of Life
Inventory (PedsQLTM), version 4.0 [13], which was com-
pleted by both children and their parents. This consists of
age-specific (6–12 years; 12–18 years) questionnaires,
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with 23 questions covering four domains (physical, emo-
tional, social functioning, and school functioning); higher
scores indicate better HRQOL, and changes in PedsQL
scores of between 4.36 and 9.67 points, depending on the
domain, are considered clinically significant [14]. Treat-
ment satisfaction in adults was measured by means of the
Diabetes Treatment Satisfaction Questionnaire, status ver-
sion (DTSQs) [15, 16]. The DTSQs consists of eight items
(score 0–6) assessing current therapy, convenience, flexi-
bility, diabetes knowledge, willingness to continue with
therapy, willingness to advocate treatment, perceived
hypoglycaemia, and perceived hyperglycaemia. The vali-
dated treatment satisfaction questionnaire was only avail-
able for adults, hence could not be conducted in the
paediatric population. Due to the multicentre nature of the
study a satisfactory validated adult, diabetes-specific QOL
questionnaire was not available in all necessary languages.
Use of medical resources
Data on medical resource use (diabetes-related hospital-
izations and their duration, diabetes-related emergency
department visits, unscheduled visits, and number and
length of telephone consultations) and time lost from
school or work were collected on the electronic case report
form at each study visit in both arms.
Statistical methods
All analyses were performed on the intention-to-treat (ITT)
population, which included all randomized patients irre-
spective of their adherence to treatment or protocol viola-
tions. The per-protocol population (PP) included patients
compliant with the protocol who used the sensor at least
70 % of the required time. Missing data within each treat-
ment period were replaced according to the last observation
carried forward (LOCF) principle, and possible carryover
effects were minimized using a 4-month washout period
[12]. HbA1c levels in the sensor-On and sensor-Off treat-
ment periods were compared by means of an analysis of
covariance (ANCOVA) model with adjustment for period
effect and subject as random effect. The average daily
number of finger-prick tests for self-monitoring of blood
glucose (SMBG), and the average daily insulin dose were
compared in the two treatment arms using a mixed model
with subject as random effect and adjustment for period
effect and age group (children/adolescents or adults).
The analysis of factors predictive of end-of-period
HbA1c was performed using a multiple imputation linear
mixed model adjusted for period effects. Factors including
sequence, treatment, age group, baseline HbA1c, average
total daily dose, SMBG, hospitalizations, telephone calls,
and additional visits, number of boluses, basal rates, and
bolus wizard use were considered.
Treatment satisfaction in adults was analysed by linear
mixed models. DTSQs perceived frequency of hyperglyca-
emia and perceived frequency of hypoglycaemia were trea-
ted individually in these analyses, as per DTSQs user
instructions. HRQOL in children and adolescents was ana-
lysed using linear mixed models adjusted for baseline
HbA1c, study period, age group (5–7, 8–12, 13–17 years),
and percentage of sensor usage. Generalized linear mixed
models were used to analyse the occurrence of hospitaliza-
tions and additional health care visits, the duration of hos-
pitalizations, the number of additional visits, and the number
of telephone consultations during each treatment period.
Analyses were performed using SAS (version 9.3)
software (SAS Institute, Cary, NC, USA), and P values
below 0.05 were considered significant.
Results
A total of 153 patients with type 1 diabetes (81 adults, 72
children and adolescents) were randomized, 77 to the On/
Off sequence and 76 to the Off/On sequence. Overall, 15
patients withdrew during the study, but all randomized
patients were included in the analysis of the primary end-
point, the difference in HbA1c between the sensor-On and
sensor-Off arms. All 72 children and 79 adults were
included in analyses of patient-reported outcomes.
HRQOL and treatment satisfaction
Changes in children’s self-reporting of HRQOL, and par-
ents’ proxy assessments, between the Sensor-On and Sen-
sor-Off arms are summarized in Table 1. There were no
significant changes in children’s self-reports in overall
HRQOL scores or in any HRQOL domain, as assessed by
the PedsQL. There were statistically significant decreases
in parents’ proxy ratings for the total PedsQL score and for
all domains except the emotional domain, but in each case,
the changes were smaller than those considered being
clinically significant [14], and hence they were not regar-
ded as clinically relevant.
In adults, treatment satisfaction measured by the DTSQs
increased significantly during the sensor-On arm, com-
pared with the sensor-Off arm (P = 0.012, Table 2), and
this was associated with significant improvements in
treatment convenience (P = 0.033) and flexibility
(P = 0.034). There were no significant differences in the
perceived frequency of hypoglycaemia or hyperglycaemia
during the sensor-On arm. A per-protocol analysis showed
Acta Diabetol (2014) 51:845–851 847
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that sensor use was significantly (P = 0.027) associated
with treatment satisfaction.
Medical resource use
Use of medical care resources during the sensor-On and
sensor-Off arms is summarized in Table 3, and an analysis
by age group for those items where significant differences
between arms were observed is summarized in Table 4.
The number of telephone calls showed significant differ-
ence between arms (Table 3). Analysis by age group
showed that adult patients made significantly fewer addi-
tional telephone consultations during the sensor-On period,
compared with the sensor-Off period (Table 4). In children,
during the sensor-On period, telephone consultations were
approximately 3 min longer on average (P = 0.0055),
compared with the sensor-Off arm. In both adults and
children, there were no statistically significant differences
in the number of diabetes-related hospitalizations between
the sensor-On and sensor-Off arms, although the mean
duration of hospitalization tended to be shorter during the
sensor-On arm (1.80 vs 2.33 days, respectively).
In a per-protocol analysis, children who used their
sensors more than 70 % of the time (i.e. C5 days per
week) missed significantly less time from school during the
sensor-On period, compared with the sensor-Off period
(mean 0.38 vs 1.24 days/child/6 months, respectively,
P = 0.0046). There was no significant difference in the
per-protocol analysis of days lost from work in the adult
cohort.
Of the factors modelled to predict end-of-period HbA1c,
only the administration of one more bolus per day
(P = 0.01) and the use of sensor (being on sensor-ON,
P \ 0.001) were associated with a decrease in HbA1c.
Discussion
These results show that the addition of CGM in patients
receiving CSII therapy improves metabolic control [11],
reflected as lower HbA1c, can be accomplished without a
significant burden on patients or an increase medical
resource use. From the patient’s perspective, CGM does
not adversely affect HRQOL in children, while adults
report greater satisfaction with treatment. Indeed, this was
confirmed by the per-protocol analysis showing positive
association between sensor usage [70 % and treatment
satisfaction. This latter finding is important because treat-
ment satisfaction has been suggested to be an indicator of
better outcomes in chronic conditions such as diabetes [16].
From the perspective of the healthcare system, there was
no difference in the number of visits or of diabetes-related
hospitalizations, although the duration of hospitalization
tended to be shorter during the Sensor-On arm. There was
also no increased exposure to severe hypoglycaemia, and
the time spent with blood glucose below 70 mg/dl was
significantly reduced [11]. The incidence of diabetic ke-
toacidosis episodes was very low and did not differ
between the two arms.
It could be anticipated that the introduction of CGM
may increase anxiety and burden for both parents and
patients, resulting in a decrease in their HR-QOL.
Although the results were not significant in children, there
was a tendency towards negative results in all domains
except emotional. For the parents, this negative impact
could have resulted from a too short follow-up period to
ameliorate this anxiety. Surprisingly, the lack of burden or
deterioration in QOL in children could show either a faster
adaptation to the therapy or that the value of the device
outweighed the burden.
Table 1 Changes in children’s self-reported health-related quality of













Physical -0.11 ± 1.01 0.917 -4.22 ± 1.35 0.003a
Psychosocial -0.59 ± 1.19 0.623 -5.08 ± 1.59 0.002a
Emotional 0.53 ± 1.54 0.734 -1.57 ± 1.57 0.318a
Social -0.35 ± 0.94 0.715 -3.75 ± 1.51 0.015a
School -1.40 ± 1.63 0.396 -6.14 ± 1.84 0.001a
Overall
HRQOL
-0.31 ± 0.84 0.712 -3.92 ± 1.18 0.002a
HRQOL was measured using the paediatric quality of life inventory
(PedsQLTM) [10]
a Clinical relevant changes were as defined by Jaeschke et al. [14]
Table 2 Change in treatment satisfaction measured using the Dia-
betes Treatment Satisfaction Questionnaire status version (DTSQs)
[12] in the sensor-On arm, compared with the sensor-Off arm
DTSQs item Change versus baseline P
Current therapy 0.19 0.062
Perceived hyperglycaemia -0.23 0.231
Perceived hypoglycaemia 0.22 0.205
Convenience 0.32 0.033
Flexibility 0.29 0.034
Diabetes knowledge 0.06 0.466
Continue with therapy 0.20 0.075
Advocate treatment 0.15 0.15
Overall treatment satisfaction 1.16 0.010
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The SWITCH study has shown that increasing the
number of boluses [11] and wearing the sensor (sensor-On)
are predictive of reducing end-of-period HbA1c.
Each centre in the study decided how to train subjects in
the study, whether individually or in groups. Three study
visits were allocated to education, which could take up to
1 h each. This may have resulted in the high sensor usage
reported in the study [11] as education could enhance
therapy motivation and may also explain the higher TS in
the per-protocol population. Adult patients made more
telephone consultations in the sensor-Off arm. The children
made longer telephone consultations during the sensor-On
arm; these calls were only 3 min longer. This suggests that
the sensor assists self-management in adults, whereas the
additional information provided by CGM in children may
require an additional 3 min of healthcare professional time
during the initiation of CGM, to advise and train
effectively.
Children who used the sensor frequently missed signif-
icantly fewer days of school, which could in turn result in
parents missing fewer days of work. Parents missing work
to care for children were not measured as part of the adult
cohort missed days work, which was not significant. Thus,
the use of CGM could offer potential savings for society.
Together, these results suggest that the addition of CGM to
CSII results in better metabolic control without imposing
an additional burden on the patient or increasing medical
resource use and offers the potential for cost offsets.
These findings are consistent with those of a previous
study from the Juvenile Diabetes Research Foundation
(JDRF) CGM trial, which found little change in QOL
measures in children and adults using CGM, compared
with patients using self-monitoring of blood glucose,
although patients reported high levels of satisfaction with
CGM [17]. Similarly, in the STAR (Sensor-augmented
pump Therapy for A1c Reduction)-3 study, the use of
CGM with pump therapy was found to offer significant
advantages in terms of treatment satisfaction for both adult
and paediatric patients and their caregivers [18]. These
high levels of treatment satisfaction are related both to
factors such as convenience and flexibility, as in the
present study, and to decreased concerns about hypogly-
caemia [7, 17–19]. The SWITCH study results are also
consistent with observational studies in everyday life that
show that the use of CGM resulted in an even greater
decrease in the number of SMBG performed. [19, 20].
Table 3 Mean (±SD) use of health care resources during the sensor-On and sensor-Off arms for the total population
Sensor-On Sensor-Off Difference P
Total daily insulin dose (U100, units/day) 48.9 ± 3.7 47.3 ± 3.7 1.64 0.0638
Finger-prick tests per day 5.0 ± 0.3 5.5 ± 3.7 -0.56 \0.0001
At least one adverse event 44.9 % (36.4–53.7)* 50.4 % (41.7–59.1 %)* -5.5 % 0.3467
At least one hospitalization 6.9 % (3.7–12.4 %)* 4.4 % (1.9–9.6 %)* 2.5 % 0.3634
At least one diabetes-related hospitalization 2.5 % (0.9–6.8 %)* 0.6 % (0.1–4.5 %)* 1.9 % 0.2138
Hospitalization duration (days) 1.8 (1.0–3.2)* 2.3 (1.1–5.0)* 0.5 0.5783
At least one additional visit 12.9 % (8.2–19.7 %)* 11.9 % (7.4–18.6 %)* 1.0 % 0.7997
Number of additional visits 0.1 (0.1–0.2)* 0.1 (0.1–0.2)* 0 0.9859
Number of additional telephone calls** On/Off: 0.5 (0.4–0.8)* On/Off: 0.4 (0.3–0.7* On/Off: 0.1 On/Off: 0.3553
Off/On: 0.5 (0.3–0.8)* Off/On: 1.0 (0.7–1.4)* Off/On: -0.4 Off/On: \ 0.0001
Duration of additional telephone calls (min) 6.8 ± 1.0 5.5 ± 1.0 1.3 0.0696
* 95 % CI ** results presented by treatment sequence
Table 4 Mean (±SD) number of finger-prick tests, number and duration of additional telephone calls, by age group (NS not significant)
Children Adults
Sensor-On Sensor-Off P Sensor-On Sensor-Off P
Number finger-prick tests per day 4.6 ± 0.2 5.2 ± 0.2 \0.0001 5.4 ± 0.2 5.8 ± 0.2 0.0075


















Duration of additional telephone calls
(min)
7.6 ± 0.6 4.7 ± 0.7 0.0055 6.0 ± 0.7 6.3 ± 0.7 Ns
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There is evidence that CGM has the potential to offer
both short-term and long-term benefits, not only in terms of
clinical outcomes, but also in HRQOL in patients with type
1 diabetes. Short-term benefits may arise as a result of both
easier decision-making about insulin therapy and decreased
fear of hypoglycaemia, whereas long-term benefits may be
attributable to the avoidance of vascular complications
resulting from intensive glycaemic control [21]. The
SWITCH showed that adding CGM improved short-term
treatment satisfaction in adults and that the introduction of
a new technology does not have a significant negative
impact on children’s quality of life.
The results may have been improved using the DTSQ
change version (DTSQc), which is more responsive to
improvements in treatment satisfaction than the DTSQs,
especially when there are ceiling effects [22]. Thus, the
DTSQs may be less sensitive to changes in patients who
are already satisfied with their treatment. However, it is
noteworthy that no decline in treatment satisfaction was
seen in the Sensor-On arm and that there were significant
improvements in ratings for treatment convenience and
flexibility.
In terms of study limitations, it should be noted that all
patients were experienced users of modern diabetes tech-
nology (all patients were required to have been using CSII
for at least 6 months, although they had not previously
used CGM), so these findings may not apply to all patients
with type 1 diabetes. Instruction in the use of CGM
requires clinician–patient contact, and there are currently
no agreed protocols for the incorporation of CGM into
routine clinical practice [23]. Another limitation is that the
duration of additional telephone consultations was self-
reported by study staff on the electronic case report form.
In addition, treatment satisfaction was measured only in
adults as no validated paediatric TS questionnaire was
available; hence, HRQOL was measured only in children.
In conclusion, the addition of CGM to CSII improves
metabolic control concomitantly reducing the time spent in
hypoglycaemia. Treatment satisfaction is increased in
adults, and there is no adverse effect on self-reported
quality of life in children. Importantly, these benefits are
achieved without significantly increasing medical resource
use. From the health care perspective, both the potential
long-term benefit of improved metabolic control in terms
of reducing long-term complications [1, 2] and the poten-
tial for short-term benefits may offer opportunities for cost
offsets. The SWITCH study adds to the growing body of
evidence for the convincing benefits of CGM in terms of
health outcomes, HRQOL, treatment satisfaction, and
medical resource use.
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